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Abstract
Sulfatide is a glycosphingolipid known to interact with several extracellular matrix proteins, such as tenascin-C which is
overexpressed in many types of cancer including that of the colon. In view of the limited success of chemotherapy in
colorectal cancer and high toxicity of doxorubicin (DOX), a sulfatide-containing liposome (SCL) encapsulation approach was
taken to overcome these barriers. This study assessed the in vitro cytotoxicity, biodistribution, therapeutic efficacy and
systemic toxicity in vivo of sulfatide-containing liposomal doxorubicin (SCL-DOX) using human colonic adenocarcinoma HT-
29 xenograft as the experimental model. In vitro, SCL-DOX was shown to be delivered into the nuclei and displayed
prolonged retention compared with the free DOX. The use of this nanodrug delivery system to deliver DOX for treatment of
tumor-bearing mice produced a much improved therapeutic efficacy in terms of tumor growth suppression and extended
survival in contrast to the free drug. Furthermore, treatment of tumor-bearing mice with SCL-DOX resulted in a lower DOX
uptake in the principal sites of toxicity of the free drug, namely the heart and skin, as well as reduced myelosuppression and
diminished cardiotoxicity. Such natural lipid-guided nanodrug delivery systems may represent a new strategy for the
development of effective anticancer chemotherapeutics targeting the tumor microenvironment for both primary tumor and
micrometastases.
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Introduction
Colorectal cancer is the third most common cause of cancer-
related deaths worldwide [1,2], with up to 25% of patients
presenting with metastatic disease. Despite surgery and chemo-
therapy, many of these patients eventually succumb to metastatic
diseases. Adjuvant therapies, including radiotherapy and chemo-
therapy, are designed to target residual tumor cells. In stage III
patients with colorectal cancer, chemotherapy remains the main
treatment strategy [3]. However, the success of these therapies is
limited by the emergence of therapy-resistant cancer cells as well
as dose-limiting toxicities [4]. Over the past few decades,
nanoscale therapeutic systems have emerged as novel therapeutic
modalities for combating cancer [4]. The nanoparticle formula-
tions of traditional free anticancer drugs may have improved
pharmacokinetics and biodistribution profiles, enhanced antitu-
mor efficacy, as well as reduced toxicity to healthy tissues.
Liposomal drugs were the first approved and widely used such
nanomedicine for the treatment of cancers [5,6]. Liposomes are
microscopic phospholipid vesicles with a bilayered membrane
structure. Preclinical and clinical studies have shown that the
pharmacokinetic profiles, as well as the targeting specificities, of
liposomes can be controlled and modified to reduce the side effects
of encapsulated drugs and enhance their efficacy [7,8,9].
We have recently developed a novel liposomal carrier system
that is composed of two lipids found in humans, sulfatide and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) [12,13]. Un-
der physiological pH, DOPE confers stability to sulfatide-contain-
ing liposomes (SCL) via its inhibitory effects on liposome fusion, as
the incorporation of sulfatide into DOPE vesicles greatly enhances
the stability of the liposomes formed, even in the presence of
plasma, presumably due to the hydration of the negatively charged
sulfate head-group of the glycosphingolipid [10]. We have also
demonstrated that the interaction between sulfatide and tenascin
mediates the binding of SCL to the ECM and endocytic uptake of
the liposomes by tumor cells at least in vitro [10,11].
The targeted delivery of anticancer agents to the tumor
microenvironment is a promising avenue for the therapy of
metastatic colorectal cancer. Tenascin-C, a large extracellular
matrix hexabracchion glycoprotein, is highly expressed in the
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microenvironment of most solid tumors, including colorectal
cancers, but is absent or greatly reduced in most adult tissues [14].
Our sulfatide-containing liposomal carrier system thus represents
a new class of natural lipid-guided intracellular delivery system
targeting the tumor microenvironment. In exploring such a new
direction for the development of more effective anticancer
chemotherapeutics, it is important to understand the in vivo
behavior of the nanocarrier, as the unique distribution governed
by the properties of the nanocarrier can change the therapeutic
efficacy as well as alter the toxicity profile of the encapsulated
drug. In this study, we utilize a mouse xenograft model of human
colorectal adenocarcinoma (HT-29) that is known to express
tenascin-C [15,16] and a widely used chemotherapy drug,
doxorubicin (DOX), as a model payload to study the biodistribu-
tion, antitumor efficacy and toxicity of sulfatide-containing
liposomal carrier system.
Materials and Methods
Ethics Statement
The Deakin University Animal Welfare Committee has
approved all animal protocols used in this research.
Cell Culture
The human colorectal adenocarcinoma cell line HT-29 was
purchased from American Type Culture Collection (ATCC,
Manassas, VA). McCoy’s 5A (modified) medium was purchased
from InvitrogenTM (Australia). Fetal bovine serum (FBS) was
purchased from Hyclone (Canada). Trypsin was purchased from
InvitrogenTM (Australia). Tissue culture flasks were purchased
from BD FalconTM (Australia). Glass bottom dishes were
purchased from MatTek Corporation (Ashalnd, MA, US). HT-
29 Cells were cultured in McCoy’s 5A medium supplemented with
10% fetal bovine serum, penicillin (50 U/mL), and streptomycin
(50 mg/mL) in a humidified atmosphere containing 5% CO2 and
95% air at 37uC.
Preparation of SCL-DOX
Liposomes were prepared according to a previously published
method with some modifications [10]. Briefly, DOPE unilamellar
vesicles containing 30% (molar ratio) sulfatide were prepared by
a hydration method followed by polycarbonate membrane
extrusion. DOPE (13.35 mM) and sulfatide (6 mM, Avanti Polar
Lipids, Inc.) were dissolved in a mixture of chloroform and
methanol (2:1, v/v), and the lipid mixture, composed of DOPE/
sulfatide (3:7, mol/mol), was transferred to glass tubes. Samples
were then reduced to a minimum volume under a nitrogen stream,
and stored under vacuum for 24 h at 4uC to completely evaporate
the organic solvent. The thin lipid films were hydrated by the
addition of 1 mL of 250 mM ammonium sulfate (pH 8.5). The
samples were then placed in an ice-water bath and sonicated
under nitrogen for 2.5 min with 50% amplitude using a sonicator
(Sonics & Materials, Inc). Following sonication, the liposomes were
formed via extrusion through polycarbonate membranes (Avanti
Polar Lipids, Inc.) with consecutive pore sizes of 400 nm for 14
times, 200 nm for 14 times and 100 nm for 19 times at room
temperature. To establish a trans-bilayer ammonium sulfate
gradient, the extruded liposomes were dialyzed against a 250-fold
volume of 10% sucrose in 25 mM Trizma at pH 8.5 at 4uC for
24 h. The external buffer was changed three times during dialysis.
After dialysis of the liposomes, DOX, in 10% sucrose at a final
concentration of 5 mg/mL, was added to the liposomes at a drug-
to-lipid ratio of 0.3:1 (w/w), followed by incubation in a water bath
at 60uC for 1 h. Non-encapsulated DOX was removed by size
exclusion chromatography using a Sephadex G-50 column. The
concentration of phospholipids (DOPE) in the liposomes was
determined as previously described [17]. The vesicle size and zeta
potential of SCL were measured using Zetasizer Nano ZS Particle
Characterization System from Malvern? Instruments (Malvern,
UK). The DOX loaded into SCL was quantified using a fluores-
cence detector in High Performance Liquid Chromatography
(HPLC).
Chromatographic instrumentation was used based on a pre-
viously published method with some modifications [18,19]. Briefly,
the HPLC system (Milford, MA, USA) used in this study consists
of a Waters e2695 Separation Module and a Waters 2475 Multi l
Fluorescence Detector. The excitation and emission wavelengths
were set at the 470 nm and 585 nm, respectively. Chromato-
graphic separation was performed using a Nova-PakH C18 column
(3.96150 mm i.d., 4 mm, Waters, USA) with a Nova-PakH C18
guard column (3.9620 mm i.d., 4 mm, Waters, USA). A mixture
of methanol and 10 mM phosphate buffer (pH=3.0) was used as
the mobile phase. The flow-rate used in the assay was 1 mL/min
and the column was maintained at 4065uC throughout the
chromatographic process.
Analysis of Cytotoxicity
The effect of free DOX or SCL-DOX on HT-29 cytotoxicity
was determined using the MTT cell proliferation assay [20,21].
HT-29 cells were seeded at a density of 26103 cells per well in
a 96-well plate in 100 ml McCoy’s 5A medium containing 10%
FBS. Free DOX solution and SCL-DOX were added to each well
24 h after plating (final concentration 0–100 mg/mL). After 48 h
of incubation at 37uC, 5% CO2, absorbance was measured at
a wavelength of 570 nm using a VICTOR TM X5 Multilabel
HTS Plate Reader (PerkinElmer Life and Analytical Sciences).
Cytotoxicity was expressed as a percentage of control cells. The
inhibition concentration 50% (IC50), defined as the dose of agents
that inhibited 50% of cell growth, was interpolated from the
growth curves using SPSS 13.0 [18,19]. All experiments were
performed in triplicate and repeated thrice.
Confocal Microscopy Analysis for Cellular Uptake and
Retention of SCL-DOX
HT-29 cells (16105 cells/well) were seeded in 35 mm glass
bottom dishes and incubated at 37uC in 5% CO2 for 24 h. The
medium was then replaced with full culture medium containing
2 mg/mL free DOX or SCL-DOX. Twenty-four hours later, cells
were washed twice with phosphate buffered saline (PBS) and
imaged for cellular uptake studies. For retentions studies, cells
were first exposed to 2 mg/mL free DOX or SCL-DOX in full cell
culture medium for 24 h and then washed twice with PBS. Cells
were then incubated with fresh cell culture medium and serially
imaged at 1 h, 2 h, 4 h, and 24 h using a Fluoview FV10i
fluorescence laser scanning confocal microscopy (Olympus,
Japan).
Analysis of Pharmacokinetic Properties in vivo
Male Sprague-Dawley (SD) rats (200 to 250 g) were housed in
a temperature controlled room (2561uC) with a 12-h light-dark
cycle. Rats were fed ad libitum with a standard diet but were fasted
overnight before free DOX or SCL-DOX administration. All
procedures involving animal experimentation were approved by
the Deakin University Animal Welfare Committee.
To investigate the pharmacokinetics (PK) properties of SCL-
DOX in vivo, healthy SD rats were injected intravenously with
free DOX or SCL-DOX via the tail vein with a single dose of
Therapeutic Efficacy of SCL-DOX in Colon Cancer
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5 mg DOX/kg. Blood was serially collected from the same animal
in heparinised tubes from the tail at 2 min, 0.5 h, 2 h, 6 h, 24 h
and 48 h. After collection, samples were centrifuged at 3,0006g at
4uC for 10 min to separate the plasma. To determine DOX levels
in plasma, 495 ml of methanol and 405 ml of phosphate buffer
were then added to 100 mL plasma, vortexed for 1 min, and
centrifuged at 21,0006g for 10 min at 4uC. The supernatant was
transferred to another tube followed by the addition of 2 mL of
perchloric acid (35%, v/v). The samples were vortexed for 1 min,
and centrifuged at 21,0006g for 10 min at 4uC, followed by the
measurement of DOX concentration using HPLC.
Tumor Implantation, Treatment and Evaluation
Xenograft tumors were established in 6 weeks old female
BALB/c-Foxn1nu mice that were purchased from The Animal
Resources Centre (Perth, Australia). All animal experiments were
performed in accordance with the guidelines of institutional
Animal Welfare Committee of Deakin University. Mice were kept
under pathogen-free conditions in TECNIPLAST SealsafeTM
Individually Ventilated Cages (Buguggiate, Italy) at (2561uC) and
a 12-h light/12-h dark cycle. They were fed ad libitum with
a standard diet.
HT-29 cells used for xenograft tumors were prepared by
trypsinization. The cells were washed and resuspended at
a concentration of 36107 cells/mL in PBS, which was then
inoculated subcutaneously (s. c.) into the right flank of the mice.
Tumor size was assessed using a digital caliper every other day
after implantation and approximate tumor burden (mm3) was
calculated as length6width2/2 (V= lw2/2), where length and
width are the longest and shortest axis in millimeters [22].
For the tumor uptake study, mice with tumors of ,150 mm3
were treated with free DOX or SCL-DOX (5 mg/kg DOX or
equivalent) via tail vein injection. Twenty-four hours after
injection, mice were sacrificed by injection of Lethabarb R
(100 mg/kg) and tumors were processed as previously described
[23,24]. DOX concentration in tissue was determined using
HPLC.
For therapeutic experiments, mice were treated when the
xenograft tumors reached 35 mm3. Mice received an injection of
saline, free DOX (5 mg/kg), SCL-DOX (5 mg/kg in DOX) or
blank SCL via tail vein twice a week for 3 weeks. Tumor growth
was monitored by measuring tumor diameters every other day
with a caliper and animal weights were monitored at the same
time. The end point of this study was defined as the tumor load
reaching 1700 mm3.
Analysis of Systemic Toxicity
To evaluate the general toxicity of free DOX and SCL-DOX,
blood was collected when the mice for therapeutic experiments
were sacrificed. Blood cells counts and troponin were analyzed by
a veterinary pathology laboratory (Gribbles Veterinary Pathology,
Clayton, Victoria, Australia). Blood smears were obtained for each
animal to obtain a relative white cell count adapted from the Fonio
method for platelet counting [25,26], with minor modifications.
Slides were stained with Giesma and an area of the blood smear
was chosen where the red cells abutted each other but did not
overlap, with consecutive fields chosen to eliminate bias. The total
number of white cells per 1500 red cells were counted (n= 3 for
each slide) and compared for each group.
Data Analysis
All the results are presented as means and standard error
(mean6S.E.). The pharmacokinetic parameters were calculated
from the average plasma concentrations using the pharmacoki-
netic software DAS 2.0 software (Mathematical Pharmacology
Professional Committee of China, Shanghai, China). The
differences in the mean values among different groups were
determined by a one-way analysis of variance (ANOVA) using
SPSS 13.0 program. Significance was considered at values of
p,0.05.
Results
Characterization of SCL
The diameter of SCL incorporating DOX was found to range
within 92.361.3 nm (mean6S.E.; n = 10) with polydispersity
index (PDI) of 0.1560.01 (mean6S.E.). At an initial weight ratio
of DOX to DOPE of 0.3:1, the SCL had an average DOX
entrapment efficiency of 94.1162.27% (mean6S.E). The zeta
potential value of SCL was 226.3862.20 mV (mean6S.E.). The
DOX to DOPE weight ratio after DOX encapsulation into SCL
was 0.5:1.
Intracellular Uptake and Retention of SCL-DOX in HT-29
Cells
Taking advantage of the natural fluorescent property of DOX,
the cellular uptake and retention of free DOX or SCL-DOX was
studied using laser scanning confocal microscopy. HT-29 cells
were incubated with 2 mg/ml DOX or SCL-DOX for 24 h.
Following washing, the cellular uptake of different formulations of
DOX was examined. As shown in Figure S1 (low magnification)
and Figure 1 (high magnification), both free DOX and SCL-DOX
were taken up by the colorectal adenocarcinoma cells and there
were accumulations of DOX in the nucleus in both groups
(Figure 1), albeit cells treated with free DOX showed slightly
stronger red fluorescence (DOX) than those treated with SCL-
DOX after 24 h incubation. Interestingly, the retention of SCL-
DOX in HT-29 cells was better than that for free DOX. As shown
in Figure S2A (low magnification) and Figure 2A (high magnifi-
cation), following washing with PBS and incubation in fresh media
for 4 h, the DOX fluorescence in the free DOX group decreased
significantly. Moreover, cells treated with free DOX showed
diminished red fluorescence 24 h after washing. Conversely, the
red fluorescence for SCL-DOX was more stable compared to that
of the free DOX group. Even 24 h after washing, DOX
fluorescence could be readily observed in the nuclei of cells
treated with SCL-DOX (Figure S2B and Figure 2B). The
enhanced retention of SCL-DOX in vitro suggests that the SCL
formulation of DOX might exhibit better treatment efficacy
in vivo.
In vitro Cytotoxicity
To study the in vitro cytotoxicity, HT-29 cells were exposed to
various concentrations of free DOX or SCL-DOX for 48 h, and
the cell viability was measured using the MTT assay. As shown in
Table 1, the IC50 of DOX for HT-29 cells was 1.7460.10 mg/mL
while the IC50 of SCL-DOX was 2.7760.06. Thus, under in vitro
conditions where cells were exposed to a constant concentration of
the agents throughout the entire assay period, free DOX was more
toxic than SCL-DOX. Empty SCL did not show any effects on cell
survival (data not shown).
Improved Pharmacokinetic Properties of SCL in Healthy
SD Rats
The pharmacokinetic properties of both free DOX and SCL-
DOX were studied in healthy male SD rats. The serum clearance
kinetics of free DOX and SCL-DOX was compared as shown in
Therapeutic Efficacy of SCL-DOX in Colon Cancer
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Table 2. In our study, the clearance rate of DOX encapsulated by
SCL-DOX (1.39 L/h/kg) was significantly lower than that of
DOX solution (2.68 L/h/kg, p,0.01), suggesting a different rate
of clearance of SCL-DOX compared to free drug. Moreover, the
area under the plasma concentration-time curves during the study
period (AUC0–48 h) of DOX delivered through SCL was 2.37-fold
higher than free DOX (p,0.01). Thus, DOX could display
a significantly reduced clearance rate as well as enhanced
bioavailability when administered entrapped in SCL.
Biodistribution and Tumor Uptake Advantages of SCL-
DOX
Studies comparing the accumulation of free DOX or SCL-
DOX in tumors and organs were performed in a BALB/c nude
mice HT-29 tumor xenograft model. Animals were injected i.v.
with a single dose of free DOX or SCL-DOX (5 mg/kg) and there
was no statistically significant difference in DOX concentration in
the kidneys between the two treatment groups 24 h after
administration. The lungs and liver showed higher DOX
accumulation (4.74-fold and 12.94-fold, respectively) with SCL-
DOX treatment (Figure 3A), and the spleen, a major organ of the
reticuloendothelial system, showed a 17-fold higher DOX
accumulation with SCL-DOX treatment. However, SCL-DOX
treatment in the two principal organs that display dose-limiting
toxicities of DOX clinically, namely the skin and heart, decreased
the DOX accumulation to 59.0% (0.03960.001 mg/g versus
0.06660.003 mg/g) and 77.4% (0.95660.073 mg/g versus
1.23560.083 mg/g) compared to the free DOX, respectively
(Figure 3A and 2B). Moreover, SCL encapsulation significantly
enhanced DOX accumulation (1.3-fold; 0.06060.005 mg/g versus
0.04760.003 mg/g) in the xenograft tumor compared to the free
DOX (Figure 3D), clearly confirming the enhanced intratumoral
DOX delivery by SCL-DOX in vivo.
Enhanced Therapeutic Efficacy of SCL-DOX
We evaluated the antitumor activity of SCL-DOX using the
BALB/c nude mice HT-29 tumor xenograft model. Once the
tumor had grown to approximately 35 mm3, we divided the
animals randomly into four groups (n = 5,10) in order to
minimize difference in weight and tumor size among the groups.
The following regimens were administered i.v. twice a week for 3
weeks: (i) saline; (ii) empty SCL; (iii) free DOX (5 mg/kg) and (iv)
SCL-DOX (5 mg/kg). The body weight of the animals and the
tumor size were then monitored until the size of the tumor in the
control animals reached the end point of the study. As presented in
Figure 4, for the control groups of mice receiving saline or empty
SCL, the treatment did not show any efficacy, and the mean
tumor sizes at the end of the study were 1129.03655.06 mm3, and
1188.636137.54 mm3, respectively (mean 6 S.E.; n = 5,6). The
SCL-DOX treatment group demonstrated superior efficacy, with
a final mean tumor load of 586.52629.63 mm3, compared to
809.13643.75 mm3 in the free DOX group. Thus, compared to
saline or free DOX treatment, the efficacy of SCL-DOX to
suppress tumor growth at the dose of 5 mg/kg was significantly
improved by ,1.9-fold and ,1.4-fold, respectively.
Next, we compared the survival rates of tumor-bearing mice
following the four different treatment regimens. As shown in
Figure 5, median survival times for the four different groups were
Figure 1. Intracellular uptake of SCL-DOX in HT-29 cells. HT-29 cells were incubated with 2 mg/mL free DOX or equivalent SCL-DOX for 24 h.
Following two washes with PBS, cells were imaged with a confocal fluorescence microscope. (A) Cells treated with free DOX. (B) Cells treated with
SLC-DOX. Red: fluorescence from DOX; blue: nuclei stained with Hoechst 33342. Scale bars: 10 mm.
doi:10.1371/journal.pone.0049277.g001
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26 days (saline), 33 days (free DOX), 36 days (SCL-DOX) and 32
days (blank SCL), respectively. Thus, SCL-DOX treatment
increased medium life-span by 38.5% compared to the saline
control group, by 12.5% compared to the blank SCL group and
by 9.1% compared to the free DOX group. These experiments
demonstrated that the administration of SCL-DOX in 6 doses
over a three-week period not only afforded better inhibition of
tumor growth but also improved the survival of xenograft-bearing
animals.
Reduced Systemic Toxicity of SCL-DOX
DOX-induced cardiomyopathy is one of the key dose-limiting
toxicities of the drug [27]. Cardiac troponin-T is released from
DOX-damaged myocytes [28], therefore, measurement of serum
levels of this protein provides a sensitive assessment of early
cardiotoxicity of DOX. The method used in the present study has
a cut-off threshold of ,0.01 mg/L for normal subjects [29]. As
shown in Table-3, the free DOX treatment resulted in a 75-fold
higher troponin serum level compared to the controls, confirming
the known cardiotoxicity of the free drug. However, no elevation
of serum troponin was observed for the SCL-DOX treatment
group, which remained below cut-off levels, as with the control
groups, indicating that treating xenograft-bearing mice with 6
doses of SCL-DOX over the period of 4 weeks had minimal
cardiotoxicity. To investigate whether encapsulation of DOX into
SCL had any impact on the severity of bone marrow suppression
(myelosuppression), the most common adverse effect of DOX
chemotherapy [27], we studied the changes in peripheral white
blood cells count. As shown in Figure 6, there was no statistically
significant difference in the total number of white blood cells
between the saline treated or SCL-DOX-treated groups. Further-
more, compared with mice treated with free DOX, those treated
with SCL-DOX had a 2.0-fold and a 3.3-fold higher count for
lymphocytes and monocytes, respectively. Thus, our data suggest
that SCL-DOX has minimal cardiotoxicity and significantly
reduced myelosuppression.
Discussion
This study is the first to evaluate the tissue distribution, in vivo
anticancer activities and toxicity profile of SCL-DOX in
a xenograft mouse model of human colorectal adenocarcinoma.
We have shown several important points: (a) SCL-DOX was
readily taken up by colon cancer cells and displayed prolonged
retention; (b) encapsulation of DOX in SCL resulted in a decreased
distribution of the drug to the principal sites of acute and chronic
toxicity of free DOX, namely the heart and the skin, as well as
markedly lowered cardiotoxicity and myelosuppression; (c) sulfa-
tide-containing liposomal drug displayed an enhanced therapeutic
efficacy in a mouse model of human colorectal adenocarcinoma.
The intracellular uptake of SCL in glioma cells was shown to be
a result of endocytic uptake of the liposomes in previous work [11].
In this study, we confirmed the intracellular uptake of SCL-DOX
by human colorectal adenocarcinoma cells, HT-29, using confocal
microscopy. Importantly, we demonstrated that the encapsulated
chemotherapy drug was delivered intracellularly to the site of
action, the nuclei, of the HT-29 cells (Figures 1 and 2).
Furthermore, the delivered liposomal drug was retained by the
tumor cells even 24 h after washing. Our in vitro cytotoxicity
study compared the viability of colorectal cancer cells treated with
SCL-DOX and free DOX using the MTT assay and showed that
both forms possess overt cytotoxicity. Interestingly, the SCL-DOX
has an IC50 59% higher than that of free DOX (Table 1). This is
consistent with observations from others that the IC50 of the free
and liposomal drug, when assayed in vitro, varies dependent on
the cell lines used and the nature of the liposomes. For example,
Wang et al. found in the rat prostate cancer cell line MLLB2, the
IC50 of the liposomal formulation was significantly lower than free
DOX [30]. In a study of resistant MCF-7/ADR cells, the
liposomal DOX showed a 30-fold lower IC50 compared to free
DOX [31]. However, in other studies free DOX seems to have
higher intracellular uptake and displays higher cytotoxicity than
that of liposomal DOX. For example, in the hepatocellular
carcinoma cell line, HepG2, free DOX has been indicated to
possess a higher cytotoxicity compared to that of DOX-loaded
stealth liposomes [24]. Furthermore, polyethylene glycol (PEG)
coated-liposomal DOX has been shown to have less toxicity than
free DOX in the glioma cell line, U-87 cells [10]. It is important to
appreciate that the in vivo pharmacokinetics are very different
between liposomal DOX and free DOX. The half-life of liposomal
DOX can be several days while free DOX can be eliminated in
a few minutes in vivo [32,33,34]. In cell culture dishes, cells are
exposed to a constant drug concentration throughout the entire
assay period, and often take up free DOX more rapidly than
liposomal formulation [35]. Furthermore, cells for MTT assays are
mostly cultured in monolayers, which have a spatial organization
drastically different from the in vivo 3-dimensional tissue archi-
tecture [36]. Thus, comparison of IC50 between a free drug and
Figure 2. Intracellular retention of SCL-DOX in HT-29 cells. HT-29 cells were first incubated with 2 mg/mL free DOX or equivalent SCL-DOX for
24 h. After two washes with PBS to remove the drugs, cells were cultured in fresh full culture medium followed by imaging serially at 1 h, 2 h, 4 h and
24 h using fluorescence confocal microscopy. (A) Cells treated with free DOX. (B) Cells treated with SLC-DOX. Red: fluorescence from DOX; blue:
nuclei stained with Hoechst 33342. Scale bars: 10 mm.
doi:10.1371/journal.pone.0049277.g002
Table 1. Mean IC50 values (mg/ml of doxorubicin) for
treatment with free DOX and SCL-DOX.
Cell line Free dox (mg/ml) SCL-dox (mg/ml)
HT-29 1.7460.10 2.7760.06
Data are shown as means6S.E. of triplicate in three independent experiments.
doi:10.1371/journal.pone.0049277.t001
Table 2. Comparison of pharmacokinetic parameters of free
DOX and SCL-DOX in SD Rats.
Formulations
Parameter Free DOX SCL-DOX
Dox dose (mg/kg) 5 5
AUC0–48 (mg/Lh) 1358.00628.55 3264.62679.65**
CL (L/h/kg) 2.6860.22 1.3960.04**
Pharmacokinetic parameters were calculated after the i.v. injection of free DOX
or SCL-DOX in healthy SD rats at a dose of 5 mg/kg. Data are shown as
means6S.E. of at least three independent experiments.
AUC0–48: Area under the plasma concentration-time curve.
CL: Total body clearance.
**, P,0.01 compared to free DOX.
doi:10.1371/journal.pone.0049277.t002
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a nanoparticle-formulation of the drug in vitro provides a mea-
surement of the cytotoxicity under a constant concentration during
a chosen assay period, and therefore it may not be able to provide
a reliable prediction of the therapeutic efficacy in vivo [37]. In the
present study, although the IC50 of SCL-DOX was higher than
that of free DOX in HT-29 cells in vitro, the SCL formulation was
shown to display a much improved tumor inhibitory effect over
the free DOX in HT-29 tumor-bearing nude mice (Figures 4 and
5).
Gastrointestinal tumors are known to be relatively resistant to
chemotherapeutics. In 80% of untreated colon tumors, there is an
elevated level of multidrug-resistant I (MDR I) gene [38]. The
comparison of pharmacokinetic properties between the free DOX
and SCL-DOX in healthy SD rats displayed the significant
decreased of clearance rate of SCL-DOX compared to free DOX
(p,0.01). The same improvement was found in the area under the
plasma concentration-time curve (Table 2), indicating reduced
clearance rate and enhanced bioavailability of our SCL-DOX.
Notably, significantly higher concentrations of DOX in tumor
from SCL-DOX treated mice were found after single administra-
tion (p,0.05). Moreover, it is interesting to note that SCL
encapsulation not only resulted in a significant increase in tumor
uptake in vivo, but also enhanced the anti-tumor efficacy of DOX
in HT-29 tumor-bearing nude after repeated administration. As
the statistically significant difference in tumor growth between free
DOX and SCL-DOX groups appeared after the 5th administra-
tion (Figure 4), the therapeutic efficacy may be attributed to the
preferential accumulation of SCL-DOX in the tumor via the
enhanced permeability and retention effect over the period of
multiple administrations. Moreover, after intracellular delivery,
the SCL-DOX was retained in the tumor cells much better than
free DOX (Figure 2). Thus, the increased DOX concentration in
tumors treated with SCL-DOX is consistent with a better
treatment efficacy in vivo.
In most cases, cancer chemotherapy is limited by the low
therapeutic index of the anticancer drugs due to serious toxicity to
normal tissues. Indeed, the therapy-limiting toxicity of DOX is
cardiomyopathy, which may lead to congestive heart failure and
death [27]. Encapsulation of free DOX using a cyanoacrylate
nanoparticle shifted toxicity from the heart to the kidney [39],
while the PEGylated liposomal DOX (Doxil) accumulates in skin,
resulting in a shift in the toxicity profile from cardiotoxicity and
myelosuppression to cutaneous toxicity, known as palmar-plantar
erythrodysesthesia [40]. We aimed to develop a nanoliposome that
improves the biodistribution characteristics and changes the
toxicologic properties of the encapsulated drug. In our preclinical
toxicology experiments, we utilized the intended clinical admin-
istration route, i.e. intravenous injection, throughout the studies
with the HT-29 tumor-bearing mice models. Our data (Figure 3)
demonstrated that the accumulation of liposomal DOX in the skin
and heart were significantly lower than that of free DOX. Since
tissue levels of DOX were reduced by SCL delivery, the decreased
concentration of DOX at these sites is likely to result in a reduced
risk of the development of side effects. Indeed, the biochemical and
haematological analyses (Figure 6 and Table 3) demonstrated that
the improved therapeutic efficacy of SCL-DOX was obtained
without an increase in toxicity to the heart or to the bone marrow.
It is noteworthy that the troponin level was significantly lower in
the SCL-DOX group than that of the free DOX group. As for the
indicators of myelosuppression, the higher level of total white cell
numbers, lymphocytes and monocytes in the SCL-DOX group
indicated that formulation via SCL decreased the toxicity of
myelosuppression of the encapsulated drug. The increased
accumulation of SCL-DOX in the liver, spleen and lung
compared to the free DOX may be related to the particle size
of SCL, as nanoparticles with sizes of 100–200 nm preferentially
accumulate in organs of the reticuloendothelial system [41,42,43].
By encapsulating drugs in nanoparticles, nanomedicine reduces
the drug concentration in normal host tissues and increases the
concentration of active drug within the tumor. To further improve
the selectivity and specificity, it is desirable to actively target the
nanodrugs to the site of the tumor. Targeting nanodrugs using
antibodies that recognize the tumor-associated antigens is a widely
adopted approach. However, its application might be limited by
altered expression or low percentages of tumor cells that express
any given antigen. Therefore, the development of alternative
targeted drug delivery systems may have important implications
for future novel anticancer therapeutics. We have previously
demonstrated that sulfatide mediates the binding and endocytic
uptake of SCL in tumor cells via the interaction with tenascin-C
[11]. The extracellular matrix is a major constituent of the tumor
microenvironment that is very different from that of their normal
Figure 3. Biodistribution and tumor uptake of doxorubicin
encapsulated in sulfatide-containing liposome in xenograft-
bearing mice. Nude mice bearing human colorectal cancer HT-29
xenografts were treated with 5 mg/kg free DOX or SCL-DOX i.v. Mice
were euthanized 24 h later. Organs and tissues were harvested, washed,
weighed, and the DOX was extracted and quantified. Data are shown as
means 6 S.E. (n = 5,6). *, P,0.05 compared to free DOX; **, P,0.01
compared to free DOX.
doi:10.1371/journal.pone.0049277.g003
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counterparts. Tenascin-C is a large extracellular matrix hexab-
rachion glycoprotein and is absent or greatly reduced in most
normal adult tissues. Tenascin-C is highly expressed in the
majority of malignant solid tumors, including gliomas, and cancer
of the breast, uterus, ovaries, prostate, colon, stomach, pancreas,
lung, liver, skin and kidney [14]. Furthermore, high tenascin-C
expression correlates with a low survival prognosis in cancers such
Figure 4. Sulfatide-containing liposomal doxorubicin produced more reduction in tumor volume. Mice bearing HT-29 xenografts were
injected i.v. with saline, 5 mg/kg of free DOX, SCL-DOX or empty SCL twice a week for 3 weeks as indicated, starting on the day when tumor volume
reached ,35 mm3. Data shown are means 6 S.E. (n = 5,6). *, P,0.05 compared to saline; **, P,0.01 compared to saline; #, P,0.05 compared to
free DOX; &&, P,0.01 compared to blank SCL; &&&, P,0.001 compared to blank SCL.
doi:10.1371/journal.pone.0049277.g004
Figure 5. Sulfatide-containing liposomal doxorubicin en-
hanced survival. The Kaplan-Meier survival curve shows improvement
of life span of xenograft-bearing mice treated with SCL-DOX (n= 9,10
per group). Mice were treated as indicated in Figure 3 and were
sacrificed throughout the study period upon reaching our study end
point.
doi:10.1371/journal.pone.0049277.g005
Figure 6. Sulfatide-containing liposomal doxorubicin treat-
ment had significantly reduced myelosuppression. HT-29
xenograft-bearing mice were treated as indicated in Figure 3. Blood
was collected immediately after the mice were sacrificed upon reaching
the end point. Data shown are means 6 S.E. (n = 3,5). *, P,0.05
compared to saline; ***, P,0.001 compared to saline; #, P,0.05
compared to free DOX; ##, P,0.01 compared to free DOX.
doi:10.1371/journal.pone.0049277.g006
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as glioma, breast, colon and lung carcinoma. In addition to its
roles in promoting tumor cell proliferation and angiogenesis,
tenascin-C has recently been shown to provide breast cancer cells
with a key metastatic niche to colonize the lungs by promoting
tumor cell dissemination and survival during the early steps of
metastasis and enhancing the fitness of the disseminated cancer
cells at the site of colonization [44]. Thus, the production of
tenascin-C enhances the ability of micrometastatic colonies to
survive and expand. Given that up to 20% of new cases of
colorectal cancer present with metastatic disease, and of the
patients who present with localized disease, about 20% will
subsequently relapse with distant metastases [4], targeting
tenascin-C would constitute a promising strategy in our effort to
combat micrometastasis. Sulfatide has been shown to bind to
several extracellular matrix proteins, including tenascin-C [45,46].
In this study, we further demonstrated the in vivo utilities of the
SCL in enhanced efficacy in colorectal cancer xenografts known to
express tenascin-C as well as reduced concentration and toxicity in
tissues that are susceptible to the main side effects of the
encapsulated drug, i.e. the heart, the bone marrow and the skin.
Future research in combining active targeting ligands, such as
antibodies and aptamers, which target cancer stem cell surface
makers with natural lipid-guided intracellular delivery, may open
a new direction for the development of more effective anticancer
nanotherapeutics.
In conclusion, we have demonstrated that SCL-DOX showed
an improved toxicity profile and enhanced efficacy in a human
colorectal cancer xenograft model. It may therefore provide
a potent and safe nanomedicine platform for treatment of cancer
that has overexpression of sulfatide-binding proteins, especially
tenascin-C. Functionalizing SCL with antibodies or aptamers may
further enhance the clinical utilities of this natural lipid-guided
liposomal formulation of anticancer drugs for both primary tumor
and micrometastasis via effective targeting the tumor microenvi-
ronment.
Supporting Information
Figure S1 Intracellular uptake of SCL-DOX in HT-29
cells. HT-29 cells were incubated with 2 mg/mL free DOX or
equivalent SCL-DOX for 24 h. Following two washes with PBS,
cells were imaged with a confocal fluorescence microscope. (A)
Cells treated with free DOX. (B) Cells treated with SLC-DOX.
Red: fluorescence from DOX; blue: nuclei stained with Hoechst
33342. Scale bars: 200 mm.
(TIF)
Figure S2 Intracellular retention of SCL-DOX in HT-29
cells. HT-29 cells were first incubated with 2 mg/mL free DOX
or equivalent SCL-DOX for 24 h. After two washes with PBS to
remove the drugs, cells were cultured in fresh full culture medium
followed by imaging serially at 1 h, 2 h, 4 h and 24 h using
fluorescence confocal microscopy. (A) Cells treated with free
DOX. (B) Cells treated with SLC-DOX. Red: fluorescence from
DOX; blue: nuclei stained with Hoechst 33342. Scale bars:
200 mm.
(TIF)
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